Once-daily dosing of NCX 470 demonstrated noninferiority compared with latanoprost in lowering IOP in patients with open-angle glaucoma or ocular hypertension in the phase 3 Mont Blanc clinical trial.
The trial, which enrolled 691 participants at 56 sites in the U.S. and one site in China, investigated the efficacy and safety of NCX 470 ophthalmic solution 0.1% for IOP reduction from baseline at six timepoints: 8 a.m. and 4 p.m. at week 2, week 6 and month 3.
IOP decreased 8 mm Hg from baseline to 9.7 mm Hg in (Read more...)